Integra

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

Retrieved on: 
Sunday, November 5, 2023
Food, Lipopolysaccharide, Prior, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Integra, Pomerantz, LLP, Risk, Patient, Private investigator

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Integra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Integra LifeSciences Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IART

Retrieved on: 
Sunday, November 5, 2023
Titan, FDA, Food, Court, I-Space (Chinese company), Advertising, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, Integra, Class, Insurance, Tobacco

WHAT TO DO NEXT: To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

INTEGRA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Integra To Contact Him Directly To Discuss Their Options

Retrieved on: 
Saturday, November 4, 2023
FDA, Lipopolysaccharide, Court, Advertising, PMA, Woman, LLP, Boston, Patient, Failure, Infection, Cryptocurrency, Dietary supplement, Medical device, Pharmaceutical industry, Integra

NEW YORK, Nov. 04, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) and reminds investors of the November 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.
  • Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Integra’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

INTEGRA ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Integra LifeSciences Holdings Corp. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 4, 2023
FDA, Complaint, Lipopolysaccharide, Person, Telephone, Court, PMA, P.C, Integra, District court, Letter, Patient, Kleffman v. Vonage Holdings Corp., Infection, Dietary supplement, Pharmaceutical industry

Investors have until November 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.
  • Consequently, on November 2, 2018, the FDA issued a Notice of Inspectional Observations on Form 483 (the “2018 Form 483”) to put Integra on notice of those violations.
  • Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Integra LifeSciences Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IART

Retrieved on: 
Thursday, November 2, 2023
Titan, FDA, Food, Court, I-Space (Chinese company), Advertising, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, Integra, Class, Insurance, Tobacco

WHAT TO DO NEXT: To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Integra LifeSciences (IART) Investors with Substantial Losses to Contact its Attorneys Before Nov. 13th Deadline in Securities Fraud Class Action

Retrieved on: 
Thursday, November 2, 2023
Person, FDA, Good manufacturing practice, Lipopolysaccharide, PMA, EPS, Hagens Berman, Kleffman v. Vonage Holdings Corp., SAN, Pharmaceutical industry, Life insurance, Integra

SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Integra LifeSciences Holdings Corp. (NASDAQ: IART) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Integra LifeSciences Holdings Corp. (NASDAQ: IART) investors who suffered substantial losses to submit your losses now .
  • Integra LifeSciences Holdings Corp. (IART) Securities Fraud Class Action:
    The litigation focuses on Integra’s disclosures related to the FDA’s findings of Good Manufacturing Practices violations at its Boston Facility.
  • 26, 2023, when Integra revealed that it paused production at the Boston Facility.
  • “We’re focused on investors’ losses and whether Integra misled investors about its compliance with worldwide Good Manufacturing Practices,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Integra LifeSciences Holdings Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 13, 2023 – (NASDAQ: IART)

Retrieved on: 
Thursday, November 2, 2023
Integra, FDA, Fraud, PMA, NEXT, Holding company, Security (finance)

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Integra LifeSciences Holdings Corporation.

Key Points: 
  • NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Integra LifeSciences Holdings Corporation.
  • Shareholders who purchased shares of IART during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • DEADLINE: November 13, 2023 Shareholders should not delay in registering for this class action.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

DEADLINE ALERT: Bernstein Liebhard LLP Reminds Integra LifeSciences Holding Corporation Investors of Upcoming Deadline

Retrieved on: 
Wednesday, November 1, 2023
Court, Integra, District court, Advertising, Action Replay, Security (finance)

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Integra LifeSciences Holding Corporation (NASDAQ: IART)?
  • Did you lose money in your investment in Integra LifeSciences Holding Corporation?
  • Bernstein Liebhard LLP , a nationally acclaimed investor rights law firm, reminds investors of Integra LifeSciences Holding Corporation (“Integra” or the “Company”) (NASDAQ: IART) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
  • If you purchased or acquired Integra common stock, and/or would like to discuss your legal rights and options please visit Integra LifeSciences Holding Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] .

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

Retrieved on: 
Wednesday, November 1, 2023
Suite, FDA, Lipopolysaccharide, News, Court, PMA, Integra, GPM, Defendant, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Integra LifeSciences Holdings Corporation(IART) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Wednesday, November 1, 2023
FDA, Telephone, Court, PMA, NEXT, LLP, Levi, COST, CLASS, Dietary supplement, Integra

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integra investors who were adversely affected by alleged securities fraud between March 11, 2019 and May 22, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    IART investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.